technology
real time visualization of tumor tissue
One in eight women will be diagnosed with breast cancer at some point in their lifetime¹, with 60-70% of women undergoing breast-conserving surgery with the aim of removing the malignancy while preserving the breast. Obtaining clear margins is the key surgical goal and remains a challenging.
Tozuleristide is an investigational agent designed for real-time direct visualization of tumor tissue, which may help improve achieving clear margins and overall resection rates.
¹American Cancer Society, 2024.
Tumor Paint® (tozuleristide) visualization of lumpectomy (top) indicates close margin. Intraoperative visualization of residual cancer on cavity wall (bottom) allows surgeon to see and remove cancer during initial surgery.
Clinical trials
Patients who participate in clinical trials are critical in advancing medical science. Blaze thanks the patients, caregivers, and healthcare providers involved in its clinical trials.
Blaze is focused on developing Tumor Paint® products. Our first Tumor Paint® candidate, tozuleristide (BLZ-100) has extensive clinical experience within brain and breast cancers, demonstrating excellent safety and diagnostic performance profiles.
Pipeline
expanded access
Blaze Bioscience’s development resources are focused on development of tozuleristide, our investigational product. Blaze Bioscience does not have an active Expanded Access Program at this time and is not accepting or considering requests for expanded access use. Should we develop an Expanded Access Program in the future, this policy will be updated.